Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

@article{Gianni2014NeoadjuvantAA,
  title={Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.},
  author={Luca Gianni and Wolfgang Eiermann and Vladimir Fedorovich Semiglazov and A{\~n}a Lluch and Sergei Alexeevich Tjulandin and Milvia Zambetti and Angela Moliterni and Federico V{\'a}zquez and Mikhail J Byakhov and Mikhail R. Lichinitser and Miguel {\'A}ngel Climent and E Ciruelos and Bel{\'e}n Ojeda and Mauro Mansutti and Alla A Bozhok and Domenico Magazz{\`u} and Dominik Heinzmann and Jutta Steinseifer and Pinuccia Valagussa and Jos{\'e} Baselga},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 6},
  pages={640-7}
}
BACKGROUND In our randomised, controlled, phase 3 trial NeOAdjuvant Herceptin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant trastuzumab significantly improved pathological complete response rate and event-free survival. We report updated results from our primary analysis to establish the long-term benefit of trastuzumab-containing neoadjuvant therapy. METHODS We did this multicentre, open-label, randomised trial in women with HER2… CONTINUE READING